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____________________________________________________________________23 
ABSTRACT 24 
 25 
The nitrogen solubility (pH 2.0–8.0), heat stability (pH 6.2–7.4) and viscosity (pH 6.2–7.4) 26 
properties of bovine milk protein isolate (MPI) and its Flavourzyme™, Neutrase™ and 27 
Protamex™ enzymatic hydrolysates were studied. Gel permeation chromatography indicated 28 
digestion of individual milk proteins in all hydrolysates. MPI had low solubility at pH 4.0–5.0; 29 
however, hydrolysis with all enzymes significantly increased solubility between pH 4.0–7.0. 30 
MPI was highly heat stable at 140 °C above pH 6.8 (>10 min). All hydrolysates coagulated 31 
within 64 s at 140 °C between pH 6.2–7.4. All hydrolysates displayed increased apparent 32 
viscosities upon exposure to simulated high temperature short time (HTST) heating and cooling 33 
conditions between pH 6.2–7.4. The results demonstrate that enzymatic hydrolysis of MPI 34 
increased protein solubility; however, the heat stability was reduced. The apparent viscosity was 35 
lower than the control at ambient temperature and increased at 90 °C. 36 
______________________________________________________________________________ 37 
  38 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
1. Introduction 39 
 40 
Bovine milk protein isolate (MPI) is a commercial ingredient prepared following ultra-41 
filtration (UF) and diafiltration (DF) of skimmed milk. The resulting permeate contains lactose, 42 
soluble minerals and non-protein nitrogen while protein, fat and colloidal minerals partition to 43 
the retentate (Mistry, 2002). The DF retentate is evaporated and spray-dried to produce MPI 44 
powder (Kelly, 2011). The typical composition of MPI powder (on a dry matter (DM) basis) is 45 
91.4% (w/w) protein, 6.1% (w/w) ash, 1.5% (w/w) fat and 1.0% (w/w) lactose (Agarwal, 46 
Beausire, Patel, & Patel, 2015).  47 
The high protein, low lactose, low fat, and innate mineral content makes MPI particularly 48 
useful for nutritional applications such as low lactose infant and medical nutrition and also, 49 
sports nutrition and weight management. MPI possesses valuable functional properties related to 50 
viscosity, foaming and emulsification enhancement (De Castro-Morel & Harper, 2002). 51 
MPI has poor water solubility, which limits its functional properties (De Castro-Morel & 52 
Harper, 2002). While MPI has a similar casein to whey protein ratio as skimmed milk (O’Regan, 53 
Ennis, & Mulvihill, 2009); its protein concentration and the serum and micellar environments are 54 
altered during the membrane filtration process (Mistry, 2002). Scanning electron microscope 55 
(SEM) images of reconstituted milk protein concentrate (85%, w/w, protein; MPC85) showed 56 
casein micelles fused together into a porous structure linked by direct intermicellar contact and 57 
short bridges composed of material exposed from the loosened micelle (Mimouni, Deeth, 58 
Whittaker, Gidley, & Bhandari, 2010). The rate-limiting factor of hydration was the release of 59 
individual micelles after gradual erosion and collapse of the micellar network (Mimouni et al., 60 
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2010). Furthermore, casein micelle network formation is increased as a function of storage time 61 
and temperature resulting in the formation of a skin-like layer on the surface of MPI powder 62 
particles (Mimouni et al., 2010).  63 
The application of increased mechanical agitation (Richard et al., 2013) and heated water 64 
(50 °C) has been shown to accelerate rehydration (Crowley et al., 2015). Addition of NaCl (Mao, 65 
Tong, Gualco, & Vink, 2012) or KCl (Sikand, Tong, Roy, Rodriguez-Saona, & Murray, 2013) to 66 
the UF retentate during DF at 100 to 150 mM resulted in 100% solubility of MPC80. Chelation 67 
of ionic calcium (Ca2+) has also been reported to positively affect MPC and MPI solubility 68 
(Bhaskar, Singh, & Blazey, 2003) and heat stability (De Kort, Minor, Snoeren, van Hooijdonk, 69 
& van der Linden, 2012). 70 
Controlled enzymatic hydrolysis using mammalian, plant and microbial sources (singly 71 
or in combination) has been used to modify the functional properties of whey proteins, caseins 72 
and MPC80. Increased solubility and decreased viscosity are typically observed with an 73 
increasing extent of protein hydrolysis due to changes in size, structure and hydrophobicity of 74 
the peptides released (El-Salam & El-Shibiny, 2017). Partial hydrolysis of whey proteins has 75 
been shown to improve heat stability and functional properties while extensive hydrolysis can 76 
negatively affect functional properties compared with the intact protein (Foegeding, Davis, 77 
Doucet, & McGuffey, 2002). Hydrolysis of caseins and sodium caseinate has been shown in 78 
several instances to improve nitrogen solubility at the isoelectric point (Chobert, Bertrand-Harb, 79 
& Nicolas, 1988; Flanagan & FitzGerald, 2003; Rajarathnam, Nongonierma, O'Sullivan, Flynn, 80 
& FitzGerald, 2016). Banach, Lin, and Lamsal (2013) hydrolysed MPC80 with chymotrypsin, 81 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
5 
 
trypsin, pepsin and papain, which resulted in an improvement of the nitrogen solubility in the pH 82 
range 4.6–7.0. 83 
There is limited information in the literature on the role of enzymatic hydrolysis on the 84 
functional properties of bovine MPI. Therefore, the objective of this study was to evaluate the 85 
functional properties of MPI hydrolysed with three proteolytic enzyme preparations: 86 
Flavourzyme™, Neutrase™ and Protamex™. The hypothesis was that enzymatic treatment 87 
would alter the functional properties of MPI, i.e., enhance nitrogen solubility, reduce viscosity 88 
and heat stability. 89 
 90 
2.  Materials and methods 91 
 92 
2.1. Materials 93 
 94 
Bovine MPI (88%, w/w, protein) was purchased from Kerry Ingredients (Listowel, 95 
Ireland). Flavourzyme™ (500L), Neutrase™ (0.8L) and Protamex™ (1.5L) were obtained from 96 
Novozymes (Bagsvaerd, Denmark). 2,4,6-Trinitrobenzenesulfonic acid (TNBS) was obtained 97 
from the Medical Supply Company (Dublin, Ireland). Hydrochloric acid (HCl), sodium 98 
hydroxide (NaOH), high performance liquid chromatography (HPLC) grade water, acetonitrile 99 
(ACN), 0.2 µm PTFE syringe filters, 0.2 µm cellulose acetate filters and Whatman No. 1 filter 100 
paper and were purchased from VWR (Dublin, Ireland). Trifluoroacetic acid (TFA), 101 
tris(hydroxymethyl)aminomethane (Tris), sodium phosphate monobasic, sodium phosphate 102 
dibasic, sodium dodecyl sulphate (SDS), standards for molecular mass distribution [i.e., bovine 103 
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serum albumin (BSA), β-lactoglobulin (β-Lg), α-lactalbumin (α-La), aprotinin, bacitracin, Leu-104 
Trp-Met-Arg, Asp-Glu and Tyr], mass spectrometry (MS) grade water and ACN were purchased 105 
from Sigma Aldrich (Dublin, Ireland). All other chemicals were of analytical grade unless 106 
otherwise stated. 107 
 108 
2.2. Milk protein isolate hydrolysis 109 
 110 
A solution of MPI (10%, w/w, protein) was dispersed in distilled water under constant 111 
agitation for 120 min in a water bath (Lauda E100, Lauda Brinkmann, Lauda-Königshofen, 112 
Germany) set at 50 °C. The pH of the solution was adjusted to pH 7.0 using 2 M NaOH and the 113 
sample was allowed to equilibrate for a further 30 min at 50 °C with the pH readjusted as 114 
necessary. The enzyme preparations were added to the MPI solutions under agitation at an 115 
enzyme to substrate ratio (E: S) of 1:50 (w/w for Flavourzyme™ and Protamex™ or v/w for 116 
Neutrase™), on a protein basis. The pH of the enzyme-treated MPI solution was kept constant at 117 
pH 7.0 using a pH stat (718 stat Titrino, Metrohm, Herisau, Switzerland) by the addition of 2 M 118 
NaOH for a total duration of 180 min. Hydrolysate samples were removed for analysis at 2 119 
incubation times for each enzyme. The Flavourzyme™ hydrolysates FLV60 and FLV180 were 120 
taken after an incubation time of 60 min and 180 min, respectively; the Neutrase™ hydrolysates 121 
NEU30 and NEU180 were taken after an incubation time of 30 min and 180 min, respectively; 122 
the Protamex™ hydrolysates PRT30 and PRT180 were taken after an incubation time of 30 min 123 
and 180 min, respectively. The FLV60 sample was taken after 60 min incubation to achieve a 124 
degree of hydrolysis (DH) comparable with that of the NEU30 and PRT30 samples. After 125 
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sampling, the enzymes were inactivated by heating at 90 °C for 20 min in a water bath. The 126 
enzyme inactivation was confirmed using the azocasein method as described by Kilcawley, 127 
Wilkinson, and Fox (2002). The hydrolysates were then freeze-dried (Free Zone 18L, Labconco, 128 
Kansas City, MO, USA) and stored at -20 °C prior to further analysis. The control (CTRL0) 129 
corresponded to the MPI powder. A further MPI control sample (CRTL180) was prepared under 130 
the same conditions (time (180 min), temperature, pH adjustment, agitation, heat treatment, 131 
freeze drying and storage) as the hydrolysates, but without enzyme addition. 132 
 133 
2.3. Compositional analysis 134 
 135 
Protein content of the powder samples was determined in triplicate as outlined with the 136 
IDF (1993) Kjeldahl method using an Auto-Kjeldahl System K-370 (BUCHI Labortechnik AG, 137 
Flawil, Switzerland). A nitrogen-protein conversion factor of 6.25 was used. Mineral analysis 138 
was performed in triplicate by a contract laboratory, using the AOAC (2012) ICP Emission 139 
Spectrometry method (AOAC method 2011.14). 140 
 141 
2.4. Degree of hydrolysis determination 142 
 143 
The DH of each hydrolysate was determined in triplicate using the 144 
Trinitrobenzenosulfonic (TNBS) method (Adler-Nissen, 1979) as outlined by Spellman, 145 
McEvoy, O’Cuinn, and FitzGerald, (2003). The DH was expressed as the percentage of peptide 146 
bonds hydrolysed. Absorbance values were measured at 350 nm with a spectrophotometer 147 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
(Shimadzu UV mini 1240, Kyoto, Japan). The method was calibrated using Leu standards and 148 
the absorbance values were expressed as free amino group content (AN). The DH was 149 
determined using the following formula:  150 
 = 100 ×
	
	
		
       (1) 151 
where: AN1, the free amino group content of the unhydrolysed MPI proteins (mg g-1 protein), 152 
AN2, the free amino group content of the MPI hydrolysate (mg g-1 protein) and Npb the nitrogen 153 
content of the peptide bonds in the protein substrate [114.34 for MPI as previously described 154 
(Nongonierma, Lalmahomed, Paolella, and FitzGerald, 2017b)]. 155 
 156 
2.5. Molecular mass determination by gel permeation high performance liquid 157 
chromatography  158 
 159 
Molecular mass distribution of the intact and hydrolysed MPI samples was determined by 160 
gel permeation high performance liquid chromatography (GP-HPLC). GP-HPLC was carried out 161 
as previously described by Spellman, O’Cuinn, and FitzGerald (2009), using a Waters HPLC 162 
system (Milford, MA, USA) and a TSK G2000 SW separating column (600 × 7.5 mm ID, Tosoh 163 
Bioscience, Tokyo, Japan). Samples were resuspended in the mobile phase (0.1%, v/v, TFA and 164 
30% HPLC-grade acetonitrile in HPLC water) at 0.22% (w/v) protein and filtered through 0.2 165 
µm PTFE syringe filters. The flow rate was set at 0.5 mL min-1 for 60 min. The absorbance was 166 
monitored at 214 nm. 167 
 168 
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2.6. Peptide profile determination by reverse-phase ultra-performance liquid chromatography  169 
 170 
The peptide profiles of the intact and hydrolysed MPI samples was determined using an 171 
Acquity-Waters reverse-phase ultra-performance liquid chromatography (RP-UPLC) system as 172 
per Nongonierma and FitzGerald (2012). An Acquity UPLC BEH C18, 130 Å column (2.1 mm 173 
× 50 mm × 1.7 mm) and Acquity BEH C18 (1.7 mm) vanguard pre-column, from Waters, were 174 
used. Solvent A was 0.1% (v/v) TFA in MS-grade water and solvent B was 0.1% (v/v) TFA in 175 
80% HPLC grade ACN. The samples were resuspended (0.4%, w/v, protein) in solvent A and 176 
filtered using 0.2 µm cellulose acetate filters. The flow rate was set at 0.3 mL min-1 for 45 min. 177 
Elution was completed using a linear gradient of solvent A to B (0.1%, v/v, TFA and 80%, v/v, 178 
MS grade acetonitrile in MS-grade water): 0–0.28 min, 100% A; 0.28–45 min, 100–20% A. The 179 
absorbance was monitored at 214 nm and 280 nm. 180 
 181 
2.7. Amino acid analysis 182 
 183 
Total and free amino acid analysis of the intact and hydrolysed MPI samples was 184 
performed in triplicate by a contract laboratory, using the HPLC method described by Schuster 185 
(1988). 186 
 187 
2.8. Nitrogen solubility index  188 
 189 
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The nitrogen solubility of MPI and associated hydrolysates was determined using the IDF 190 
(2002) nitrogen solubility index (NSI) method at pH 2.0, 3.0, 4.0, 4.5, 5.0, 6.0, 6.5, 7.0 and 8.0, 191 
in triplicate. Sample solutions (1% protein (w/w) in distilled water) were prepared at ambient 192 
temperature (22 ± 2 °C). The pH was adjusted using 0.1 M and 1.0 M HCl or NaOH, as required. 193 
The solutions were magnetically stirred at ambient temperature for 120 min, with the pH 194 
readjusted as necessary. The samples were then allowed to stand for 2 min before centrifugation 195 
at 3000 × g for 10 min at 22 °C (Heittich Zentrifugen Universal 320R centrifuge, Andreas 196 
Heittich GmbH & Co., Tuttlingen, Germany). After centrifugation, each supernatant was filtered 197 
through Whatman No. 1 filter paper and the protein content in the filtrates were determined by 198 
the Kjeldahl method as per the IDF (1993) procedure. A nitrogen-protein conversion factor of 199 
6.25 was used. Solubility was calculated as the protein content of the supernatant expressed as a 200 
percentage of the total protein content of the initial powder sample. 201 
 202 
2.9. Heat stability analysis 203 
 204 
The heat coagulation times (HCT) of 1.5% (w/w) protein in distilled water solutions of 205 
MPI and associated hydrolysates were determined at 140 °C at pH 6.2, 6.5, 6.8, 7.1 and 7.4. The 206 
solutions were initially magnetically stirred at ambient temperature for 120 min. The solutions 207 
were then pH adjusted using 0.1 M and 1.0 M HCl or NaOH as required. The pH adjusted 208 
samples were refrigerated at 4 °C overnight. The samples were then brought to ambient 209 
temperature and pH readjusted as necessary. Aliquots (2mL) of the samples were transferred into 210 
glass tubes (10 mm × 120 mm, AGB Scientific, Dublin, Ireland) and sealed with rubber stoppers. 211 
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The tubes were placed in a metal rack and immersed in an oil bath at 140 °C (Elbanton BV, 212 
Kerkdriel, The Netherlands) with continuous oscillation. The time required to induce visual 213 
coagulation/flocculation of the sample was taken as the HCT (Flanagan & FitzGerald, 2003). 214 
Each analysis was performed in triplicate. 215 
 216 
2.10. Ionic calcium concentration 217 
 218 
Ca2+ concentration was determined in triplicate using a Ca2+ selective probe (Metrohm, 219 
Evenwood, UK). The 1.5% (w/w) protein in distilled water solutions were prepared as per the 220 
HCT samples at pH 6.2, 6.5, 6.8, 7.1 and 7.4. The pH was readjusted post overnight refrigeration 221 
if necessary. The Ca2+ selective probe was calibrated using 1.0, 5.0 and 10.0 mM calcium 222 
solutions (prepared using CaCl2 and KCl). Once calibrated, the probe was immersed in the 223 
samples, held at 25 °C and magnetically stirred for 10 min. Results were expressed in mM Ca2+ 224 
L-1 sample at the different pH values. 225 
 226 
2.11. Measurement of apparent viscosity  227 
 228 
The apparent viscosity of the intact and hydrolysed MPI samples was determined at 25, 229 
45 and 90 °C using an AR 2000ex Rheometer (TA Instruments Ltd., Crawley, UK) fitted with a 230 
standard sized concentric cylinder geometry (TA Instruments Ltd.). Solutions (5.5%, w/w, 231 
protein) were adjusted to pH 6.2, 6.8 and 7.4 using 0.1 M and 1.0 M HCl or NaOH, as required. 232 
At constant temperature a shear rate increasing from 0.01 to 300 s-1 was applied over 120 s 233 
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followed by a constant shear of 300 s-1 for a further 120 s. The viscosity of the intact and 234 
hydrolysed MPI samples was determined in triplicate at simulated pasteurisation high 235 
temperature, short time (HTST) and cooling conditions using an AR 2000ex Rheometer fitted 236 
with a starch pasting cell geometry (TA Instruments Ltd). The samples (5.5%, w/w, protein 237 
solutions) were prepared and measured at pH 6.2, 6.8 and 7.4. A fixed shear rate of 16.8 s-1 was 238 
then applied throughout. The samples were held at 65 °C for 80 s and the temperature was then 239 
increased from 65 °C to 95 °C at a heating rate of 15 °C min-1. The samples were then held at 90 240 
°C for 60 s and cooled to 10 °C at a cooling rate of 15 °C min-1 and held for a further 420 s. 241 
 242 
3. Results and discussion 243 
 244 
To date, a limited number of studies have reported on the technofunctional properties of 245 
bovine MPI hydrolysates. To our knowledge, these studies have mainly focused on the bioactive 246 
properties (antioxidant and antidiabetic) of MPI hydrolysates (Hogan, Zhang, Li, Wang, & Zhou, 247 
2009; Nongonierma, Mazzocchi, Paolella, & FitzGerald, 2017a; Nongonierma et al., 2017b). 248 
Within this study, the technofunctional properties of different MPI hydrolysates were evaluated 249 
with a particular focus on nitrogen solubility, heat stability and viscosity. 250 
During MPI hydrolysis, it was shown that the enzyme preparation as well as hydrolysis 251 
duration influenced the DH of the resultant hydrolysate (Fig. 1). Flavourzyme™ is an 252 
Aspergillus-derived enzyme preparation. Merz et al. (2016) characterised Flavourzyme™ and 253 
identified 8 different enzyme activities within this preparation consisting of 2 254 
aminopeptidases/exopeptidases, 2 dipeptidyl peptidases, 3 endopeptidases, and 1 α-amylase 255 
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activity. Neutrase™ and Protamex™ are preparations derived from Bacillus amyloliquefaciens 256 
and Bacillus spp., respectively. They both contain endoproteinase activities. Neutrase™ has been 257 
reported as having broad substrate specificity with a cleavage preference for peptide bonds 258 
located at the C-terminal side of hydrophobic amino acids (Madsen, Ahmt, Otte, Halkier, & 259 
Qvist, 1997). Protamex™ mainly contains a subtilisin-like activity and therefore cleaves peptide 260 
bonds at the C-terminal side of large bulky amino acids (Groen, Meldal, & Breddam, 1992). In 261 
this study, The DH of MPI hydrolysed with Flavourzyme™, Neutrase™ and Protamex™ as a 262 
function of hydrolysis time is shown in Fig. 1. FLV60 and FLV180 had DH values of 15.6 ± 263 
2.62% and 37.1 ± 2.23%, respectively. NEU30 and NEU180 had DH values of 15.6 ± 1.14% and 264 
22.9 ± 1.30%, respectively. PRT30 and PRT180 had DH values of 17.8 ± 2.37% and 21.6 ± 265 
1.58%, respectively. The hydrolysis of MPI with Flavourzyme™ yielded the highest DH (37.1% 266 
DH) after 180 min. This was linked to the presence of both endo- and exopeptidase activities 267 
within Flavourzyme™ (Kilcawley, Wilkinson, & Fox, 2002; Merz et al., 2016; Smyth & 268 
FitzGerald, 1998).  269 
The molecular mass distribution of the controls and hydrolysates is shown in Fig. 2. 270 
CRTL0 and CTRL180 contain components > 10 kDa, indicating intact proteins. The molecular 271 
mass of the peptides in the hydrolysates decreased with increasing hydrolysis time. Large 272 
molecular mass components (>10 kDa) were still present in FLV60 and NEU30, representing 273 
between 20 and 28% of these samples. FLV180, NEU180, PRT30 and PRT180 contained a large 274 
proportion of components <1 kDa which represented up to 64% of these hydrolysates. FLV180 275 
and PRT180 had similar levels of <1 kDa molecular mass components (64%, Fig. 2). 276 
Flavourzyme™ yielded MPI hydrolysates having the highest levels of free amino acids 277 
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compared with the other hydrolysate samples, which increased with the level of hydrolysis (Fig. 278 
3). This was linked to the exopeptidase activities within Flavourzyme™ (Merz et al., 2016). 279 
FLV60, for example, contained 1260 mg 100 g-1 of Trp and 405 mg 100 g-1 free Trp. Therefore, 280 
32% of the Trp present in FLV60 is free Trp. The free Trp increases to 58% in FLV180 (i.e., 711 281 
mg 100 g-1 free Trp expressed as percentage of 1260 mg 100 g-1 Trp). Flavourzyme™ did not 282 
release free Cys regardless of the hydrolysis duration. Hydrolysis of MPI with Neutrase™ and 283 
Protamex™ yielded lower levels of free amino acids than the Flavourzyme™ hydrolysate 284 
samples. Within the Neutrase™ hydrolysates, the level of free Val, Leu, Phe and Met increased 285 
with increasing hydrolysis time. Protamex™ MPI hydrolysates contained some free Thr, Ser, 286 
Val, Leu, Tyr, Phe and Met with levels increasing with the extent of hydrolysis. No free amino 287 
acids were detected in the control samples. The RP-UPLC peptide profile of the hydrolysate 288 
samples at 214 nm is shown in Fig. 4. Peptide peak heights eluting at lower retention times were 289 
generally higher with increasing hydrolysis times. In contrast, peptide peak heights eluting at 290 
higher retention times were in general less intense as hydrolysis proceeded. Elution with 291 
increasing ACN concentrations at shorter retention times is indicative of increasing 292 
hydrophilicity of peptides. For CTRL0 and CTRL180, characteristic individual protein peaks 293 
were not detected either at 214 nm or 280 nm indicating that the proteins in the control samples 294 
were not soluble in the mobile phase. 295 
An increase in the solubility of MPI hydrolysate samples between the isoelectric point 296 
and up to pH 7.0 was seen with increasing hydrolysis time (Fig. 5). CTRL0 and CRTL180 both 297 
had a low solubility (<10%) at the isoelectric point of caseins (pH 4.6) (Fig. 5). The controls also 298 
had <50% solubility at pH 7.0 (41 and 47% for CTRL0 and CTRL180, respectively). All MPI 299 
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hydrolysates showed enhanced solubility compared with the controls between pH 4.0 and 7.0, 300 
with the NSI increasing with increasing hydrolysis time. This increase is solubility may be 301 
attributed to the reduced molecular mass distribution and increase in the presence of hydrophilic 302 
peptides in the hydrolysate samples. FLV180, NEU180 and PRT180 displayed solubility values 303 
>80% between pH 4.0 and 8.0. FLV60 displayed the lowest increase in NSI between pH 4.0 and 304 
8.0 (57–63%). FLV60 contained the highest proportion of components >10 kDa (28%, Fig. 2) 305 
and RP-UPLC peaks at longer retention times than the other hydrolysates (Fig. 4). FLV60 had a 306 
distinct peptide peak eluting at 28 min, which was absent from FLV180, suggesting that the 307 
presence of hydrophilic peptides increased with increasing hydrolysis time. 308 
The protein, calcium and sodium contents of the controls and the hydrolysate samples are 309 
presented in Table 1. The protein and calcium results are comparable between the controls and 310 
hydrolysate samples. The sodium content of the hydrolysate samples was higher than the control 311 
samples since NaOH was used to maintain a constant pH of 7.0 during hydrolysis. The sodium 312 
content increased with increasing hydrolysis time for all enzymes. The FLV60 and the FLV180 313 
had a sodium content of 748 ± 7.29 mg 100 g-1 DM and 1124 ± 9.91 mg 100 g-1 DM respectively. 314 
The NEU30 and the NEU180 had a sodium content of 1440 ± 51.3 mg 100 g-1 DM and 1753 ± 315 
25.2 mg 100 g-1 DM respectively. The PRT30 and the PRT180 had a sodium content of 1962 ± 316 
15.3 mg 100 g-1 DM and 2281 ± 20.3 mg 100 g-1 DM respectively. The Flavourzyme™ 317 
hydrolysate samples had the lowest sodium content. Neutrase™ and Protamex™ hydrolysis 318 
required larger amounts of NaOH to maintain the pH at 7.0 during hydrolysis due to their broad 319 
specificity endopeptidase activities. Hydrolysis with exopeptidase activities does not result in a 320 
large pH decrease, due to the higher pKa of di- and tri-peptides (Spellman et al., 2003). 321 
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Therefore, a lower volume of base was required to regulate the pH during hydrolysis with 322 
Flavourzyme™ even though the DH achieved after 180 min hydrolysis was higher. FLV60 had 323 
both the lowest NSI at pH 4.0–8.0 and the lowest sodium content. The increasing sodium content 324 
of the hydrolysates with increasing hydrolysis time may also be a contributor to enhancing 325 
solubility. Mao et al. (2012) showed that sodium supplementation increased solubility of MPC80 326 
by modifying the ionic environment. CRTL180 was also shown to have slightly higher NSI than 327 
CRTL0. This increased NSI in CRTL180 may have resulted from its higher sodium content 328 
(Table 1) due to pH adjustment with NaOH. Banach et al. (2013) also showed that the freeze-329 
drying process reduced the surface hydrophobicity of MPC 80, which may also contribute to the 330 
higher NSI of CRTL180.  331 
A large reduction in the HCT of MPI was observed following enzymatic treatment (Fig. 332 
6B). The MPI substrate used in this study appears to have higher heat stability than the majority 333 
of the high protein MPCs and MPI reported in the literature (Crowley et al., 2014). The HCT for 334 
the controls increased with increasing pH to >10 min at pH 6.8 (Fig. 6A). At pH 7.4, the HCT 335 
was 27 min and 32 min for CTRL180 and CTRL0, respectively. All hydrolysate samples 336 
coagulated between 8 s (FLV60 at pH 6.2) and 64 s (NEU180 at pH 7.4) across all pH values 337 
evaluated (Fig. 6B). As per the controls, the HCT for all of the MPI hydrolysate samples 338 
increased with increasing pH. The effect of hydrolysis on the casein micelle structure, which is 339 
essential to casein heat stability, may be the cause of the reduced heat stability. Fig. 7 also 340 
showed that the Ca+2 concentration increased with increasing hydrolysis time and decreased with 341 
increasing pH values. The Ca+2 concentration of the hydrolysates was higher than that of the 342 
controls at all pH values studied. Of the hydrolysates, FLV60 and FLV180 had the lowest Ca+2 343 
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concentration at all pH values. NEU30, NEU180, PRT30 and PRT180 had comparable Ca+2 344 
concentrations at each pH value. This increase in Ca+2 is expected to have resulted from the 345 
release of Ca+2 on the breakdown of the casein micelle. In general, the enzyme preparation 346 
appears to have a minor impact on the HCT; the HCT was shown to increase with increasing 347 
hydrolysis time for all three enzyme preparations. FLV60 showed the lowest HCT at all pHs. 348 
Similarly to the lower solubility of FLV60, the HCT may have been impacted by the presence of 349 
larger molecular weight components. The Flavourzyme™ hydrolysates had both the lowest Ca+2 350 
and the lowest HCT (Fig. 7 and 6B, respectively) suggesting that while Ca+2 may play a role in 351 
the reduced heat stability of the hydrolysates, it may not be the primary driver.  352 
At 25 °C, all hydrolysate samples displayed lower apparent viscosity than the controls 353 
across all pH values at a shear rate of 300 s-1 (Table 2). The apparent viscosity decreased with 354 
increasing DH for all hydrolysate samples. The reduction in molecular mass distribution is 355 
expected to result in lower apparent viscosity of the hydrolysate samples. The apparent viscosity 356 
of the MPI controls and FLV60, NEU30, PRT30 were comparable across all pH values at 45 °C. 357 
Again, the apparent viscosity appeared to be lower at higher DH. O’Donnell and Butler (1999) 358 
showed that the apparent viscosity of MPC85 decreased with increasing temperature. While at 90 359 
°C the apparent viscosities of the FLV60, NEU30, PRT30 (3.66–4.10 mPa s) and NEU180 (3.66 360 
mPa s) were higher than CTRL0 (3.13 mPa s) and CTRL180 (3.29 mPa s) at pH 6.2. FLV180 361 
(3.28 mPa s) and PRT180 (3.10 mPa s) were comparable with the controls. At pH 6.8, FLV60, 362 
NEU30, PRT30 displayed higher apparent viscosities (3.33–3.67 mPa s) than CTRL0 (3.06 mPa 363 
s) and CTRL180 (3.18 mPa s). FLV180 (3.17 mPa s) and PRT180 (3.01 mPa s) were comparable 364 
with the controls while NEU180 displayed the lowest apparent viscosity (2.90 mPa s). At 90 °C 365 
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and pH 7.4, FLV60 displayed the highest apparent viscosity (3.55 mPa s). The apparent viscosity 366 
of NEU30 (3.17 mPa s) and PRT30 (3.00 mPa s) were similar to CTRL0 (3.02 mPa s) and 367 
CTRL180 (3.09 mPa s) while the 180 min hydrolysate samples (FLV180, NEU180, PRT180) 368 
(2.75–2.90 mPa s) displayed the lowest apparent viscosities compared with the other samples. 369 
This viscosity development in the hydrolysates at 90 °C is indicative of aggregate formation. 370 
This viscosity development at 90 °C was not evident at pH 7.4 for all hydrolysate samples 371 
(except FLV60), a result that correlates with the heat stability data, which shows increasing HCT 372 
(delayed aggregate formation) with increasing pH (Fig. 6B). Upon application of simulated 373 
HTST conditions, the viscosity of the controls and all hydrolysates was between 20–25 mPa s at 374 
the first holding temperature (65°C) for all pH values. The viscosity range reduced to 18–23 mPa 375 
s upon heating and holding at 90 °C for all samples at all pH values (Fig. 8A, B and C 376 
respectively). The hydrolysate samples, in general, displayed higher viscosity development on 377 
cooling to 10 °C at all pH values in comparison with the controls. Viscosity development 378 
decreased with increasing pH and increasing hydrolysis time. FLV60 displayed the highest 379 
viscosity development on cooling at pH 6.2 (50 mPa s), pH 6.8 (44 mPa s) and pH 7.4 (36 mPa 380 
s). In comparison, the CTRL0 viscosity values on cooling were 30 mPa s (pH 6.2), 29 mPa s (pH 381 
6.8) and 28 mPa s (pH 7.4). CTRL180 had a comparable viscosity value on cooling with CTRL0.  382 
 383 
4. Conclusions 384 
 385 
Hydrolysis of MPI with Flavourzyme™, Neutrase™ and Protamex™ resulted in 386 
enhanced nitrogen solubility between pH 4.0 and 7.0. The generation of lower molecular mass 387 
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components with increased hydrophilicity in the hydrolysate samples is expected to have resulted 388 
in increased solubility. The increased sodium content of the hydrolysates, due to NaOH addition 389 
during hydrolysis, may have contributed to enhanced solubility through modification of the ionic 390 
environment. The effect of hydrolysis on the casein micelle structure was expected to have 391 
resulted in a reduction in the hydrolysate sample’s heat stability between pH 6.2 and 7.4 in 392 
comparison with the intact MPI. While the heat stability of the hydrolysates was reduced 393 
compared with the control, typical UHT dairy products are subjected to 140 °C for 394 
approximately 5 s. This duration is lower than the HCT determined for the MPI hydrolysates, 395 
especially at higher pH values and longer hydrolysis durations. Therefore, the increase in 396 
solubility of the MPI hydrolysate samples together with a HCT up to 64 s at 140 °C would 397 
suggest that these ingredients could find applications in a range of high temperature treated food 398 
products. 399 
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Figure legends 1 
 2 
Fig. 1. Degree of hydrolysis (DH) as a function of incubation time during the enzymatic 3 
hydrolysis of bovine milk protein isolate using Flavourzyme™ (FLV) (), Neutrase™ (NEU) 4 
() and Protamex™ (PRT) (). Values represent mean, error bars represent the standard 5 
deviation, n = 3.  6 
 7 
Fig. 2. Molecular mass distribution of bovine milk protein isolate (MPI) control and 8 
hydrolysate samples. Abbreviations are: FLV60 and FLV180, Flavourzyme™ 60 min and 180 9 
min hydrolysates, respectively; NEU30 and NEU180, Neutrase™ 30 min and 180 min 10 
hydrolysates, respectively; PRT30 and PRT180, Protamex™ 30 min and 180 min hydrolysates, 11 
respectively; CTRL0, MPI control; CTRL180, MPI freeze-dried control. Mass ranges are: ,  12 
>10 kDa; , 10–5 kDa; , 5–1 kDa;  <1 kDa. Values are means (n = 3). 13 
 14 
Fig. 3. Free amino acid composition (expressed as % of total individual amino acid content) of 15 
bovine milk protein isolate (MPI) hydrolysate samples. Left right for each amino acid: , 16 
Flavourzyme™ 60 min hydrolysate; , Flavourzyme™ 180 min hydrolysate; , Neutrase™ 17 
30 min hydrolysate; , Neutrase™ 180 min hydrolysate; , Protamex™ 30 min hydrolysate ;  18 
, Protamex™ 180 min hydrolysate; , MPI control; , MPI freeze-dried control. Values 19 
are means (n = 3), error bars represent the standard deviation. 20 
 21 
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Fig. 4. Reverse phase ultra-performance liquid chromatography profiles of bovine milk protein 22 
isolate (MPI) hydrolysate samples at 214 nm [acetonitrile (ACN) gradient also shown: ˗ ˗ ˗ ˗]. 23 
Abbreviations are: FLV60 and FLV180, Flavourzyme™ 60 min and 180 min hydrolysates, 24 
respectively; NEU30 and NEU180, Neutrase™ 30 min and 180 min hydrolysates, respectively; 25 
PRT30 and PRT180, Protamex™ 30 min and 180 min hydrolysates, respectively.  26 
 27 
Fig. 5. Nitrogen solubility index (NSI, %) of bovine milk protein isolate (MPI) control and 28 
hydrolysate samples (1%, w/w, protein) rehydrated in 25 °C water, as a function of pH: , MPI 29 
control; , MPI freeze-dried control; ▲ and ˗ ˗˗ ˗, Flavourzyme™ 60 min and 180 min 30 
hydrolysates, respectively;  and ˗ ˗˗ ˗, Neutrase™ 30 min and 180 min hydrolysates, 31 
respectively;  and ˗ ˗˗ ˗, Protamex™ 30 min and 180 min hydrolysates, respectively. Values 32 
are means (n = 3). 33 
 34 
Fig. 6. Panel A: heat coagulation time (HCT) of 1.5% (w/w) protein solutions of bovine milk 35 
protein isolate (MPI) control samples as a function of pH at 140 °C: , MPI control; , MPI 36 
freeze-dried control. Panel B: HCT of 1.5% (w/w) protein solutions of bovine MPI hydrolysate 37 
samples:  and ˗ ˗˗ ˗, Flavourzyme™ 60 min and 180 min hydrolysates, respectively;  and 38 
˗ ˗˗ ˗, Neutrase™ 30 min and 180 min hydrolysates, respectively;  and ˗ ˗˗ ˗, Protamex™ 39 
30 min and 180 min hydrolysates, respectively. Values are means (n = 3). 40 
 41 
Fig. 7. Ca2+ concentration of 1.5% (w/w) protein solutions of bovine milk protein isolate (MPI) 42 
control and hydrolysate samples as a function of pH at 25 °C: , MPI control; , MPI freeze-43 
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dried control;  and ˗ ˗˗ ˗, Flavourzyme™ 60 min and 180 min hydrolysates, respectively;  44 
and ˗ ˗˗ ˗, Neutrase™ 30 min and 180 min hydrolysates, respectively;  and ˗ ˗˗ ˗, 45 
Protamex™ 30 min and 180 min hydrolysates, respectively. Values are means (n = 3). 46 
 47 
Fig. 8. Viscosity during simulated high temperature short time (HTST) and cooling of 5.5% 48 
(w/w) protein solutions of bovine milk protein isolate (MPI) control and hydrolysate samples as 49 
a function of temperature at (A) pH 6.2, (B) pH 6.8 and (C) pH 7.4: , MPI control; , MPI 50 
freeze-dried control;  and ˗ ˗˗ ˗, Flavourzyme™ 60 min and 180 min hydrolysates, 51 
respectively;  and ˗ ˗˗ ˗, Neutrase™ 30 min and 180 min hydrolysates, respectively;  and 52 
˗ ˗˗ ˗, Protamex™ 30 min and 180 min hydrolysates, respectively. Values are means (n = 3). 53 
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Table 1 1 
Protein, calcium and sodium levels in bovine milk protein isolate (MPI) control and hydrolysate 2 
samples. a 3 
Sample Protein  
(g 100 g-1) 
Calcium  
(mg 100 g-1) 
Sodium  
(mg 100 g-1) 
CTRL0 91.1 ± 0.40 2119 ± 15.3 72.9 ± 1.72 
CTRL180 91.5 ± 0.75 2157 ± 5.09 314 ± 1.53 
FLV60 90.4 ± 0.40 2137 ± 25.2 748 ± 7.29 
FLV180 91.1 ± 0.15 2140 ± 5.77 1124 ± 9.91 
NEU30 91.3 ± 0.17 2129 ± 73.7 1440 ± 51.3 
NEU180 90.4 ± 0.25 2126 ± 32.2 1753 ± 25.2 
PRT30 90.5 ± 0.36 2140 ± 36.1 1962 ± 15.3 
PRT180 90.0 ± 0.10 2139 ± 7.57 2281 ± 20.3 
 4 
a
 Abbreviations are: CTRL0, MPI control;  CTRL180, MPI freeze-dried control; FLV60 and  5 
FLV180, Flavourzyme™ 60 min and 180 min hydrolysates, respectively; NEU30 and NEU180,  6 
Neutrase™ 30 min and 180 min hydrolysates, respectively; PRT30 and PRT180, Protamex™ 60 7 
min and 180 min hydrolysates, respectively. Data are expressed per 100 g dry matter; values 8 
represent mean ± standard deviation (n = 3). 9 
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Table 2  11 
Apparent viscosity of bovine milk protein isolate (MPI) control and hydrolysate samples measured at a shear rate of 300 s-1 assessed at 12 
25, 45 and 90 °C at pH 6.2, 6.8 and 7.4. a 13 
Sample pH 6.2  pH 6.8  pH 7.4 
25 °C 45 °C 90 °C 25 °C 45 °C 90 °C 25 °C 45 °C 90 °C 
CTRL0 4.93 ± 0.08 3.66 ± 0.04 3.13 ± 0.06  4.74 ± 0.14 3.62 ± 0.05 3.06 ± 0.02  4.69 ± 0.11 3.59 ± 0.05 3.02 ± 0.02 
CTRL180 5.02 ± 0.17 3.64 ± 0.07 3.29 ± 0.09  4.93 ± 0.17 3.60 ± 0.06 3.18 ± 0.02  4.80 ± 0.16 3.61 ± 0.09 3.09 ± 0.04 
FLV60 4.03 ± 0.12 3.83 ± 0.06 4.10 ± 0.12  3.87 ± 0.18 3.59 ± 0.09 3.67 ± 0.08  3.83 ± 0.14 3.57 ± 0.04 3.55 ± 0.09 
FLV180 3.77 ± 0.15 3.68 ± 0.10 3.28 ± 0.05  3.70 ± 0.13 3.57 ± 0.13 3.17 ± 0.01  3.61 ± 0.09 3.35 ± 0.08 2.90 ± 0.02 
NEU30 3.86 ± 0.26 3.87 ± 0.08 3.71 ± 0.11  3.76 ± 0.12 3.74 ± 0.07 3.33 ± 0.05  3.67 ± 0.18 3.36 ± 0.05 3.17 ± 0.10 
NEU180 3.49 ± 0.17 3.46 ± 0.03 3.60 ± 0.05  3.46 ± 0.13 3.27 ± 0.07 2.90 ± 0.03  3.44 ± 0.14 3.28 ± 0.05 2.79 ± 0.02 
PRT30 3.85 ± 0.19 3.71 ± 0.05 3.66 ± 0.04  3.75 ± 0.20 3.36 ± 0.05 3.60 ± 0.03  3.62 ± 0.12 3.35 ± 0.09 3.00 ± 0.04 
PRT180 3.71 ± 0.19 3.60 ± 0.07 3.10 ± 0.06  3.62 ± 0.15 3.29 ± 0.06 3.01 ± 0.02  3.53 ± 0.16 3.24 ± 0.02 2.75 ± 0.03 
 14 
a
 Abbreviations are: CTRL0, MPI control;  CTRL180, MPI freeze-dried control; FLV60 and  FLV180, Flavourzyme™ 60 min and 15 
180 min hydrolysates, respectively; NEU30 and NEU180,  Neutrase™ 30 min and 180 min hydrolysates, respectively; PRT30 and 16 
PRT180, Protamex™ 60 min and 180 min hydrolysates, respectively. Values (mPa s) represent mean ± standard deviation (n = 3). 17 
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